1. Scrip
  2. >>Therapy Areas
  3. >>Anticancer

Roche's Tecentriq Positive But Not Perfect In IMpower130 First-line Lung Cancer Study

 
• By Emily Hayes

Combination with Abraxane demonstrates an overall survival benefit on top of progression-free survival, but Merck's competing Keytruda has set a high benchmark for first-line metastatic lung cancer.

Pole vault
Keytruda has set a high bar for Tecentriq in 1L NSCLC • Source: Shutterstock

Roche's combination of its PD-L1 inhibitor Tecentriq with chemotherapy in first-line treatment of non-squamous non-small cell lung cancer showed a significant 21% reduction in risk of death compared with chemo alone, but the results still may not be enough to cut it commercially.

Detailed results of the IMpower130 study were presented at the European Society for Medical Oncology (ESMO) meeting in Munich Oct. 22, following a positive top-line release in May. (Also see...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Immuno-oncology

More from Anticancer